U.S. HLA Typing Transplant Diagnostics Services Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025
U.S. HLA typing transplant diagnostics services market by technology will reach USD 431.75 million by 2025 from USD 211.98 million with a CAGR of 9.4% in the forecast period of 2018 to 2025.
The major factors driving the market are technological advancements in HLA typing, increasing number of solid organ and stem cell transplantation procedures, risen research grants, funds, and public-private investments are boosting the growth of the U.S. HLA typing transplant diagnostics services market.
The key market players for U.S. HLA typing transplant diagnostics services market are listed below:
The U.S. HLA typing transplant diagnostics services market is segmented based on technology into polymerase chain reaction (PCR), and next-generation sequencing (NGS). In 2018, polymerase chain reaction (PCR) is expected to dominate the U.S. HLA typing transplant diagnostics services market with 51.0% market share and is expected to reach USD 217.22 million by 2025, growing at a CAGR of 9.2% in the forecast period 2018 to 2025.
The polymerase chain reaction (PCR) is further sub segmented on the basis of techniques into PCR-SSP (Sequence-Specific Primer), PCR SSOP (Sequence-Specific Oligonucleotide), and PCR-SBT (Sequencing Based Typing). In 2018, PCR-SSP (Sequence-Specific Primer) is expected to dominate the U.S. HLA typing transplant diagnostics services market with 41.7% market share and is expected to reach USD 176.37 million by 2025, growing at a CAGR of 9.1% in the forecast period 2018 to 2025.
The U.S. HLA typing transplant diagnostics services market is segmented on the basis of end users into hospitals, transplant centers, specialty clinics, and academic institutes. In 2018, hospitals is expected to dominate the U.S. HLA typing transplant diagnostics services market with 36.3% market share and is expected to reach USD 159.84 million by 2025, growing at the highest CAGR of 9.7% in the forecast period 2018 to 2025.
Covered in this report
The report covers the present scenario and the growth prospects of the U.S. HLA typing transplant diagnostics services market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
The major factors driving the market are technological advancements in HLA typing, increasing number of solid organ and stem cell transplantation procedures, risen research grants, funds, and public-private investments are boosting the growth of the U.S. HLA typing transplant diagnostics services market.
The key market players for U.S. HLA typing transplant diagnostics services market are listed below:
- Proimmune Ltd.
- Creative Biolabs
- Histogenetics LLC
- The UCLA Immunogenetics Center
- Admera Health
- Quick Biology
- New York Blood Center
- The Sequencing Center
- BloodCenter of Wisconsin
- Laboratory Corporation of America Holdings
- Technology
- End-users
The U.S. HLA typing transplant diagnostics services market is segmented based on technology into polymerase chain reaction (PCR), and next-generation sequencing (NGS). In 2018, polymerase chain reaction (PCR) is expected to dominate the U.S. HLA typing transplant diagnostics services market with 51.0% market share and is expected to reach USD 217.22 million by 2025, growing at a CAGR of 9.2% in the forecast period 2018 to 2025.
The polymerase chain reaction (PCR) is further sub segmented on the basis of techniques into PCR-SSP (Sequence-Specific Primer), PCR SSOP (Sequence-Specific Oligonucleotide), and PCR-SBT (Sequencing Based Typing). In 2018, PCR-SSP (Sequence-Specific Primer) is expected to dominate the U.S. HLA typing transplant diagnostics services market with 41.7% market share and is expected to reach USD 176.37 million by 2025, growing at a CAGR of 9.1% in the forecast period 2018 to 2025.
The U.S. HLA typing transplant diagnostics services market is segmented on the basis of end users into hospitals, transplant centers, specialty clinics, and academic institutes. In 2018, hospitals is expected to dominate the U.S. HLA typing transplant diagnostics services market with 36.3% market share and is expected to reach USD 159.84 million by 2025, growing at the highest CAGR of 9.7% in the forecast period 2018 to 2025.
Covered in this report
The report covers the present scenario and the growth prospects of the U.S. HLA typing transplant diagnostics services market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
1. INTRODUCTION
1.1. Objectives Of The Study
1.2. Market Definition
1.3. Overview Of U.S. Hla Typing Transplant Diagnostics Services Market
1.4. Currency And Pricing
1.5. Limitation
1.6. Markets Covered
2. MARKET SEGMENTATION
2.1. Markets Covered
2.2. Years Considered For The Study
2.3. Currency And Pricing
2.4. Research Methodology
2.5. Primary Interviews With Key Opinion Leaders
2.6. Secondary Sources
2.7. Assumptions
3. EXECUTIVE SUMMARY
4. MARKET OVERVIEW
4.1. Drivers
4.1.1. Technological Advancements In Hla Typing
4.1.2. Increasing Number Of Solid Organ And Stem Cell Transplantation Procedures
4.1.3. Increased Research Grants, Funds, And Public-Private Investments
4.2. Restraints
4.2.1. Weak Reimbursements For Organ Donation And Transplantation Procedures
4.2.2. Expensive Ngs And Pcr-Based Devices
4.3. Opportunities
4.3.1. Rising Healthcare Infrastructure In Emerging Nations
4.4. Challenges
4.4.1. Significant Gap Between Number Of Organs Donated And Organs Required Annually
4.4.2. Lack Of Trained Staff
5. PREMIUM INSIGHTS
6. U.S. HLA TYPING TRANSPLANT DIAGNOSTICS SERVICES MARKET,
By Technology
6.1. Overview
6.2. Next-Generation Sequencing (Ngs)
6.3. Polymerase Chain Reaction (Pcr)
6.3.1. Pcr Ssop (Sequence-Specific Oligonucleotide)
6.3.2. Pcr Ssp (Sequence-Specific Primer)
6.3.3. Pcr-Sbt (Sequencing Based Typing)
7. U.S. HLA TYPING TRANSPLANT DIAGNOSTICS SERVICES MARKET,
By End-Users
7.1. Overview
7.2. Specialty Clinics
7.3. Hospitals
7.4. Transplant Centers
7.5. Academic Institutes
8. U.S. HLA TYPING TRANSPLANT DIAGNOSTICS SERVICES MARKET, COMPANY LANDSCAPE
8.1. Company Share Analysis: U.S.
9. COMPANY PROFILES
9.1. Proimmune Ltd.
9.1.1. Company Overview
9.1.2. Proimmune Ltd.: Company Snapshot
9.1.3. Product Portfolio
9.1.4. Recent Developments
9.2. Creative Biolabs
9.2.1. Company Overview
9.2.2. Creative Biolabs: Company Snapshot
9.2.3. Product Portfolio
9.2.4. Recent Developments
9.3. Histogenetics Llc
9.3.1. Company Overview
9.3.2. Histogenetics Llc: Company Snapshot
9.3.3. Product Portfolio
9.3.4. Recent Developments
9.4. The Ucla Immunogenetics Center
9.4.1. Company Overview
9.4.2. The Ucla Immunogenetics Center: Company Snapshot
9.4.3. Product Portfolio
9.4.4. Recent Developments
9.5. Admera Health
9.5.1. Company Overview
9.5.2. Admera Health: Company Snapshot
9.5.3. Product Portfolio
9.5.4. Recent Developments
9.6. Quick Biology
9.6.1. Company Overview
9.6.2. Quick Biology: Company Snapshot
9.6.3. Product Portfolio
9.6.4. Recent Developments
9.7. New York Blood Center
9.7.1. Company Overview
9.7.2. New York Blood Center: Company Snapshot
9.7.3. Product Portfolio
9.7.4. Recent Developments
9.8. The Sequencing Center
9.8.1. Company Overview
9.8.2. The Sequencing Center: Company Snapshot
9.8.3. Product Portfolio
9.8.4. Recent Developments
9.9. Bloodcenter Of Wisconsin
9.9.1. Company Overview
9.9.2. Bloodcenter Of Wisconsin: Company Snapshot
9.9.3. Product Portfolio
9.9.4. Recent Developments
9.10. Laboratory Corporation Of America Holdings
9.10.1. Company Overview
9.10.2. Laboratory Corporation Of America Holdings: Revenue Analysis
9.10.3. Product Portfolio
9.10.4. Recent Developments
9.11. Thermo Fisher Scientific Inc.
9.11.1. Company Overview
9.11.2. Thermo Fisher Scientific Inc.:Revenue Analysis
9.11.3. Product Portfolio
9.11.4. Recent Developments
10. RELATED REPORTS
1.1. Objectives Of The Study
1.2. Market Definition
1.3. Overview Of U.S. Hla Typing Transplant Diagnostics Services Market
1.4. Currency And Pricing
1.5. Limitation
1.6. Markets Covered
2. MARKET SEGMENTATION
2.1. Markets Covered
2.2. Years Considered For The Study
2.3. Currency And Pricing
2.4. Research Methodology
2.5. Primary Interviews With Key Opinion Leaders
2.6. Secondary Sources
2.7. Assumptions
3. EXECUTIVE SUMMARY
4. MARKET OVERVIEW
4.1. Drivers
4.1.1. Technological Advancements In Hla Typing
4.1.2. Increasing Number Of Solid Organ And Stem Cell Transplantation Procedures
4.1.3. Increased Research Grants, Funds, And Public-Private Investments
4.2. Restraints
4.2.1. Weak Reimbursements For Organ Donation And Transplantation Procedures
4.2.2. Expensive Ngs And Pcr-Based Devices
4.3. Opportunities
4.3.1. Rising Healthcare Infrastructure In Emerging Nations
4.4. Challenges
4.4.1. Significant Gap Between Number Of Organs Donated And Organs Required Annually
4.4.2. Lack Of Trained Staff
5. PREMIUM INSIGHTS
6. U.S. HLA TYPING TRANSPLANT DIAGNOSTICS SERVICES MARKET,
By Technology
6.1. Overview
6.2. Next-Generation Sequencing (Ngs)
6.3. Polymerase Chain Reaction (Pcr)
6.3.1. Pcr Ssop (Sequence-Specific Oligonucleotide)
6.3.2. Pcr Ssp (Sequence-Specific Primer)
6.3.3. Pcr-Sbt (Sequencing Based Typing)
7. U.S. HLA TYPING TRANSPLANT DIAGNOSTICS SERVICES MARKET,
By End-Users
7.1. Overview
7.2. Specialty Clinics
7.3. Hospitals
7.4. Transplant Centers
7.5. Academic Institutes
8. U.S. HLA TYPING TRANSPLANT DIAGNOSTICS SERVICES MARKET, COMPANY LANDSCAPE
8.1. Company Share Analysis: U.S.
9. COMPANY PROFILES
9.1. Proimmune Ltd.
9.1.1. Company Overview
9.1.2. Proimmune Ltd.: Company Snapshot
9.1.3. Product Portfolio
9.1.4. Recent Developments
9.2. Creative Biolabs
9.2.1. Company Overview
9.2.2. Creative Biolabs: Company Snapshot
9.2.3. Product Portfolio
9.2.4. Recent Developments
9.3. Histogenetics Llc
9.3.1. Company Overview
9.3.2. Histogenetics Llc: Company Snapshot
9.3.3. Product Portfolio
9.3.4. Recent Developments
9.4. The Ucla Immunogenetics Center
9.4.1. Company Overview
9.4.2. The Ucla Immunogenetics Center: Company Snapshot
9.4.3. Product Portfolio
9.4.4. Recent Developments
9.5. Admera Health
9.5.1. Company Overview
9.5.2. Admera Health: Company Snapshot
9.5.3. Product Portfolio
9.5.4. Recent Developments
9.6. Quick Biology
9.6.1. Company Overview
9.6.2. Quick Biology: Company Snapshot
9.6.3. Product Portfolio
9.6.4. Recent Developments
9.7. New York Blood Center
9.7.1. Company Overview
9.7.2. New York Blood Center: Company Snapshot
9.7.3. Product Portfolio
9.7.4. Recent Developments
9.8. The Sequencing Center
9.8.1. Company Overview
9.8.2. The Sequencing Center: Company Snapshot
9.8.3. Product Portfolio
9.8.4. Recent Developments
9.9. Bloodcenter Of Wisconsin
9.9.1. Company Overview
9.9.2. Bloodcenter Of Wisconsin: Company Snapshot
9.9.3. Product Portfolio
9.9.4. Recent Developments
9.10. Laboratory Corporation Of America Holdings
9.10.1. Company Overview
9.10.2. Laboratory Corporation Of America Holdings: Revenue Analysis
9.10.3. Product Portfolio
9.10.4. Recent Developments
9.11. Thermo Fisher Scientific Inc.
9.11.1. Company Overview
9.11.2. Thermo Fisher Scientific Inc.:Revenue Analysis
9.11.3. Product Portfolio
9.11.4. Recent Developments
10. RELATED REPORTS
LIST OF TABLES
Table 1 U.S. Hla Typing Transplant Diagnostics Services Market, By Technology, 2016– 2025 (Usd Million)
Table 2 U.S Hla Typing Transplant Diagnostics Services Market, Asp (Usd)
Table 3 U.S. Hla Typing Transplant Diagnostics Services Market, Polymerase Chain Reaction (Pcr), By Technique, 2016-2025 (Usd Million)
Table 4 U.S. Hla Typing Transplant Diagnostics Services Market, By End-Users, 2016-2025 (Usd Million)
Table 1 U.S. Hla Typing Transplant Diagnostics Services Market, By Technology, 2016– 2025 (Usd Million)
Table 2 U.S Hla Typing Transplant Diagnostics Services Market, Asp (Usd)
Table 3 U.S. Hla Typing Transplant Diagnostics Services Market, Polymerase Chain Reaction (Pcr), By Technique, 2016-2025 (Usd Million)
Table 4 U.S. Hla Typing Transplant Diagnostics Services Market, By End-Users, 2016-2025 (Usd Million)
LIST OF FIGURES
Figure 1 U.S. Hla Typing Transplant Diagnostics Services Market: Segmentation
Figure 2 U.S. Hla Typing Transplant Diagnostics Services Market:
Data Triangulation
Figure 3 U.S. Hla Typing Transplant Diagnostics Services Market:
Research Snapshot
Figure 4 U.S. Hla Typing Transplant Diagnostics Services Market:
Bottom Up Approach
Figure 5 U.S. Hla Typing Transplant Diagnostics Services Market:
Top Down Approach
Figure 6 U.S. Hla Typing Transplant Diagnostics Services Market:
Interview Demographics
Figure 7 U.S. Hla Typing Transplant Diagnostics Services Market: Segmentation
Figure 8 Drivers, Restraints, Opportunities, And Challenges Of
U.S. Hla Typing Transplant Diagnostics Services Market
Figure 9 Healthcare Expenditure In Few Emerging Countries
(2000, 2010 & 2014)
Figure 10 Number Of Donors, Recipeints And Waiting Patients In
U.S. From 2010 To 2015
Figure 11 Technological Advancements In Hla Typing, Increasing Number Of Solid Organ And Stem Cell Transplantation Procedures Are Expected To Drive The Market For U.S. Hla Typing Transplant Diagnostics Services In The Forecast Period 2018 To 2025
Figure 12 Polymerase Chain Reaction (Pcr) Segment Is Expected To Account For The Largest Share Of The U.S. Hla Typing Transplant Diagnostics Services Market In 2018 & 2025
Figure 13 U.S. Hla Typing Transplant Diagnostics Services Market:
By Technology, 2017%
Figure 14 U.S. Hla Typing Transplant Diagnostics Services Market:
By End-Users, 2017%
Figure 15 U.S. Hla Typing Transplant Diagnostics Services Market:
Company Share 2017 (%)
Figure 1 U.S. Hla Typing Transplant Diagnostics Services Market: Segmentation
Figure 2 U.S. Hla Typing Transplant Diagnostics Services Market:
Data Triangulation
Figure 3 U.S. Hla Typing Transplant Diagnostics Services Market:
Research Snapshot
Figure 4 U.S. Hla Typing Transplant Diagnostics Services Market:
Bottom Up Approach
Figure 5 U.S. Hla Typing Transplant Diagnostics Services Market:
Top Down Approach
Figure 6 U.S. Hla Typing Transplant Diagnostics Services Market:
Interview Demographics
Figure 7 U.S. Hla Typing Transplant Diagnostics Services Market: Segmentation
Figure 8 Drivers, Restraints, Opportunities, And Challenges Of
U.S. Hla Typing Transplant Diagnostics Services Market
Figure 9 Healthcare Expenditure In Few Emerging Countries
(2000, 2010 & 2014)
Figure 10 Number Of Donors, Recipeints And Waiting Patients In
U.S. From 2010 To 2015
Figure 11 Technological Advancements In Hla Typing, Increasing Number Of Solid Organ And Stem Cell Transplantation Procedures Are Expected To Drive The Market For U.S. Hla Typing Transplant Diagnostics Services In The Forecast Period 2018 To 2025
Figure 12 Polymerase Chain Reaction (Pcr) Segment Is Expected To Account For The Largest Share Of The U.S. Hla Typing Transplant Diagnostics Services Market In 2018 & 2025
Figure 13 U.S. Hla Typing Transplant Diagnostics Services Market:
By Technology, 2017%
Figure 14 U.S. Hla Typing Transplant Diagnostics Services Market:
By End-Users, 2017%
Figure 15 U.S. Hla Typing Transplant Diagnostics Services Market:
Company Share 2017 (%)
